"Leaving aside the baseline results, there is not much...

"Leaving aside the baseline results, there is not much difference between the apparent HA-I outcome and 2nd line FOLFIRI/Avastin from the ML18147 trial. And Avastin is now FDA-approved with FOLFIRI for 2nd line mCRC treatment based on that trial. Of course, that doesn't solve the immediate problem, but it does give some hope"

good think tweek...
avastin with folfiri is similar to hyact with folfiri....
But would be hyact not the cheaper thing than avastin???
That should be better for us.....and people they do not have so much money....??